What Is the Long-Term Clinical Efficacy of the Thoraflex™ Hybrid Prosthesis for Aortic Arch Repair?

• Published in: Frontiers in cardiovascular medicine 2022-02, Vol.9, p.842165-842165
• Main Authors: Tan, Sven Z C P, Jubouri, Matti, Mohammed, Idhrees, Bashir, Mohamad
• Format: Article
• Language: English
• Subjects: aneurysm; aortic arch; Cardiovascular Medicine; dissection (TAAD); frozen elephant trunk (FET); Thoraflex
• ISSN: 2297-055X; 2297-055X
• DOI: 10.3389/fcvm.2022.842165

The widespread adoption of the frozen elephant trunk (FET) technique for total arch reconstruction (TAR) in aortic arch aneurysm and dissection has led to the development of numerous commercial single-piece FET devices, each with its own unique design features. One such device, Thoraflex™ Hybrid (Terumo Aortic, Glasgow, Scotland), has enjoyed widespread use since its introduction. We present and appraisal of its long-term clinical efficacy, based on international data. Pre-, intra-, and postoperative data associated with Thoraflex™ Hybrid implantations for aortic arch dissection, aneurysm, and penetrating atherosclerotic ulcer (PAU) up to April 2019 was gathered and is presented herein. Follow-up data at discharge, 3-, 6-, 12-, 24-, 36-, 48-, 60-, 72-, and 84- months post-implantation are included. Data associated with 931 cases of Thoraflex™ Hybrid implantation are included. Mean age at implantation was 63 ± 12 years. 55% of patients included were male. Aortic dissection accounted for 48% ( = 464) of cases. Mean cardiopulmonary bypass and circulatory arrest durations were 202 +72 and 69 ± 50 min, respectively. 30-day mortality was 0.6% ( = 6), while overall mortality was 14 (1.5%). Freedom from adverse events at 84 months was 95% ( = 869). Postoperative complications included neurological deficit, multi-organ failure, cardiorespiratory compromise, and infection. Thoraflex™ Hybrid's unique design is advantageous in comparison to market alternatives. Our data is consistent with that reported in literature and suggests Thoraflex™ Hybrid is associated with favourable rates of mortality and morbidity. Thoraflex™ Hybrid remains a central player in the aortic arch prosthesis market. Its use it widespread and is associated with favourable design features and clinical outcomes relative to market alternatives.